Lonza, the world's leading contract development and manufacturing organization (CDMO), has announced the appointment of Samanta Cimitan as its new Chief Commercial Officer (CCO), Senior Vice President, and Member of the Extended Executive Committee. Cimitan, who currently serves as CEO of the Celonic Group, will join Lonza by January 1, 2027, according to a press release.
This newly created role is a strategic move under Lonza's 'One Lonza' initiative, aimed at simplifying customer engagement and delivering a harmonized go-to-market approach across all business platforms. Cimitan will lead Strategic Enterprise Account Management, Global Marketing, and Commercial Excellence, with direct responsibility for Lonza's strategic accounts. The role is designed to make it easier for customers to access Lonza's full end-to-end offerings, from early development to commercial manufacturing, across all three business platforms.
Wolfgang Wienand, CEO of Lonza, emphasized the importance of this appointment: "Samanta's appointment to the new role of Chief Commercial Officer is another important step in building One Lonza and making the full power of the Lonza Engine work for our partners in the pharmaceutical industry. Our ambition is clear: Every customer should benefit from the unique breadth of our science, technology and manufacturing capabilities, helping them translate their breakthrough innovations into viable therapies for patients worldwide."
Cimitan brings over a decade of experience in the CDMO industry, including nearly 13 years at Lonza in various commercial and strategy leadership roles. Most recently, she led the Celonic Group's transformation into a focused biologics CDMO, strengthening its commercial, operational, regulatory, and innovation capabilities. Her return to Lonza is expected to bolster the company's commercial discipline and customer partnership development.
The appointment comes at a time when the CDMO industry is facing increasing demand for integrated services and faster time-to-market for therapies. By centralizing commercial leadership, Lonza aims to provide a seamless experience for pharmaceutical and biotech clients, potentially setting a new standard for customer engagement in the contract manufacturing sector.
Industry analysts suggest that this move could have significant implications for Lonza's competitive positioning. With a unified commercial strategy, Lonza can better leverage its global footprint—operating across five continents with approximately 20,000 employees—to offer more comprehensive solutions. This could be particularly appealing to large pharmaceutical companies seeking a single partner for complex development and manufacturing needs.
For the broader industry, Lonza's focus on harmonized customer engagement may prompt other CDMOs to reassess their commercial structures. As the demand for biologics and advanced therapies grows, companies that can provide seamless, end-to-end partnerships are likely to gain a competitive edge. Lonza's half-year 2026 results, with sales of CHF 3.4 billion and CORE EBITDA of CHF 1.2 billion, indicate strong financial performance that could support further strategic initiatives.
Cimitan's appointment also highlights the importance of leadership continuity in the CDMO sector. Her previous tenure at Lonza and her recent CEO experience at Celonic provide her with a unique perspective on both the operational and strategic challenges facing the industry. As she prepares to take on her new role, stakeholders will be watching to see how she navigates the complexities of the evolving pharmaceutical landscape.
Lonza's commitment to innovation is evident in its focus on cutting-edge science, smart technology, and lean manufacturing. With Cimitan on board, the company is poised to strengthen its commercial capabilities and deliver on its purpose of "making the medicines of tomorrow." The move underscores a broader trend in the life sciences industry toward more integrated and customer-centric business models, which could ultimately benefit patients through faster access to new treatments.
For more information on Lonza and its services, visit Lonza's website.
